IGM Biosciences, Inc. has announced that it has entered into a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right $(CVR)$. This CVR entitles holders to receive 100% of any closing net cash exceeding $82.0 million, and 80% of net proceeds from certain dispositions of IGM Biosciences' product candidates and intellectual property within one year post-closing. The transaction, which has received unanimous approval from the IGM Biosciences Board of Directors, is expected to close in August 2025 following a tender offer scheduled by July 16, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。